Glenmede Trust’s Arbutus Biopharma ABUS Stock Holding History

Glenmede Trust’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-8,000	Closed	-$122K	–	2436
2014 Q4	$122K	Buy	+8,000	New	+$138K	﹤0.01%	1459

Other funds holding ABUS

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BRC

Blue Ridge Capital New York $215M AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Glenmede Trust's ABUS Position: Q1 2015 in Review

Glenmede Trust sold out of Arbutus Biopharma (ABUS) in Q1 2015, closing a stake of 8,000 shares — an estimated $122K sold.

Glenmede Trust first reported a position in ABUS in Q4 2014 and held it in 1 quarter. The position peaked at $122K in Q4 2014. 77 funds tracked by Wall St. Rank hold ABUS as of Q1 2015.

Glenmede Trust reported no remaining Arbutus Biopharma position as of Q1 2015 after selling out during the quarter.
Glenmede Trust sold 8,000 Arbutus Biopharma shares in Q1 2015, an estimated $122K.
Glenmede Trust first reported a position in Arbutus Biopharma in Q4 2014 and held it in 1 quarter.
Glenmede Trust's Arbutus Biopharma position peaked at $122K in Q4 2014.
77 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2015.

Based on Glenmede Trust's 13F filing for Q1 2015, filed 29 Apr 2015.